Triclocarbon Category I Antibacterial Efficacy Supported By Bayer Studies
This article was originally published in The Tan Sheet
Executive Summary
Triclocarbon in concentrations up to 1.5% should be included as a Category I active ingredient in the healthcare antiseptic tentative final monograph, Bayer advises FDA in a 1Dec. 28 citizen petition
You may also be interested in...
Triclosan Antiseptic Category I Status Requested By CIBA
FDA should consider new safety data supporting Category I (safe and effective) status for triclosan in the OTC Tentative Final Monograph for Health Care Antiseptic Drug Products, CIBA Specialty Chemicals and an alliance of six triclosan manufacturers/marketers state in a Sept. 13 citizen petition.
Health-Care Antiseptics OTC Labeling Amendments Proposed By CTFA/SDA
Labeling of antibacterial consumer hand and body products should include a "qualified" warning statement regarding children's use of such items, the Cosmetic, Toiletry & Fragrance Association and Soap & Detergent Association suggest in a citizen petition filed with FDA April 2.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC